Close Menu

NEW YORK (GenomeWeb) – Cepheid has launched a CE marked bladder cancer test that is currently commercially available in Germany and will launch throughout Europe in the coming months.

The Xpert Bladder Cancer Monitor test runs on the firm's GeneXpert molecular diagnostics system. It has about a 94 percent negative predictive value, so could be particularly useful in more confidently ruling out bladder cancer and reducing the need for more invasive testing, Cepheid said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.